• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Medical Tubing and Extrusion

Medical tubing and extrusion technologies

  • Technologies
    • Balloons
    • Brain-computer interfaces
    • Cardiac Implants
    • Catheters
    • Endoscopes
    • Heart valves
    • Pulsed Field Ablation
  • Components
    • Connectors
    • Needles and Injections
    • Seals
    • Tubing Components
  • Manufacturing
    • Coatings
    • Extrusions
    • Machining
    • Molding
      • Injection Molding
      • Insert molding
      • Mold Components
    • Tools
  • Materials
    • Advanced Materials
    • Metals
    • Nitinol
    • Plastics
    • Silicone
  • Business
    • Distribution Agreements
    • Legal News
    • Mergers & Acquisitions
    • Partnerships
    • Personnel Moves
  • Regulatory
    • 510(k)
    • CE Mark
    • FDA Breakthrough Designation
    • ISO Certification
    • Pre-Market Approval (PMA)
    • Recalls
  • Suppliers
  • About Us

Boston Scientific to acquire Devoro Medical and its Wolf thrombectomy platform

September 21, 2021 By Danielle Kirsh

Boston Scientific Boston Scientific today announced that it has entered an agreement to acquire Devoro Medical for more than $269 million.

Marlborough, Massachusetts-based Boston Scientific has been a strategic investor in Devoro Medical since 2019, according to the company. It has an equity stake of approximately 16%. The transaction will consist of an upfront payment of approximately $269 million for the 84% stake that is not owned and up to $67 million upon achievement of certain clinical and regulatory milestones.

Devoro Medical makes the Wolf thrombectomy platform that it designed as a non-console and lytic-free technology that targets and rapidly captures blood clots. It uses finger-like prongs to retrieve and remove thrombi in the arterial and venous systems.

“The addition of the Wolf platform advances our efforts to ensure physicians have the right tools to improve procedural efficiencies,” Jeff Mirviss, EVP and president of Boston Scientific’s peripheral interventions, said in a news release. “Clot management remains a core focus of our business, and upon commercialization, this highly differentiated technology will complement and expand our offerings to a full suite of interventional strategies for thromboembolism, which also includes the EkoSonic Endovascular System (EKOS) and the AngioJet Thrombectomy System.”

Michael Jaff — chief medical officer and VP of clinical affairs, technology and innovation at Boston Scientific — described the Wolf platform as a “compelling new option for physicians performing thrombectomy procedures. “Importantly, it is designed to target and remove clots without damaging blood vessels, while also minimizing blood-loss, which may improve outcomes.”

Senior research analyst Mike Matson of Needham & Co. in a note said he thought the Wolf platform is complementary to Boston Scientific’s peripheral interventions portfolio. “While market estimates vary, it seems clear that the thrombectomy market is large and underpenetrated.”

David Rescott and Samuel Brodovsky of Truist agreed that the Wolf system fits in well with the Boston Scientific portfolio of peripheral intervention products addressing thromboemboli, including the EkoSonic Endovascular System (EKOS) and the AngioJet thrombectomy system. The Truist analysts noted that the Wolf system does not require capital equipment and is a non-lytic based intervention.

Rescott and Brodovsky said: “We think that the company’s established presence in this segment should provide a platform to commercialize the Wolf system and potentially could drive synergies for other products within the peripheral interventions portfolio. Perhaps the biggest benefit is that the acquisition of the Wolf thrombectomy platform now provides Boston with a non-lytic based therapy to address thromboemboli in the venous and arterial segment.”

Executive editor Chris Newmarker contributed to this report. 

 

Filed Under: Catheters Tagged With: Boston Scientific, Devoro Medical

About Danielle Kirsh

Danielle Kirsh is an award-winning journalist and senior editor for Medical Tubing + Extrusion, Medical Design & Outsourcing and MassDevice. She received her bachelor's degree in broadcast journalism and mass communication from Norfolk State University and is pursuing her master's in global strategic communications at the University of Florida. You can connect with her on Twitter and LinkedIn, or email her at dkirsh@wtwhmedia.com.

Primary Sidebar

“mte
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest trends and developments in medical tubing and extrusion.
MDO ad

Sponsored Content

A new way to access scientific papers?

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Inv Logo

MASSDEVICE MEDICAL NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World
Drug Delivery Business News

Medical Tubing + Extrusion

Subscribe to our E-Newsletter
Advertise with us
About
Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS